Evidence map›Paper›PMID 40495245›Full record

ReviewMolecular neurodegeneration2025

Extracellular vesicles in TDP-43 proteinopathies: pathogenesis and biomarker potential.

Elizabeth R Dellar, Lara Nikel, Stephanie Fowler, Björn F Vahsen, Ruxandra Dafinca, Emily Feneberg, Kevin Talbot, Martin R Turner, Alexander G Thompson

Abstract readReview
In one paragraph

Review in Molecular neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Prosaposin in CNS health and disease, metabolic stress and exercise adaptation.Journal of molecular medicine (Berlin, Germany) · 2026
    Review
  7. Review
  8. Extracellular vesicle-based therapies for neurodegenerative diseases.NeuroImmune pharmacology and therapeutics · 2025
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elizabeth R DellarNuffield Department of Clinical Neurosciences, University of Oxford, Level 6, West Wing John Radcliffe Hospital, OX3 9DU, Oxford, UK.
Lara NikelNuffield Department of Clinical Neurosciences, University of Oxford, Level 6, West Wing John Radcliffe Hospital, OX3 9DU, Oxford, UK.
Stephanie FowlerOxford-GSK Institute of Molecular and Computational Medicine, University of Oxford, Oxford, UK.
Björn F VahsenNuffield Department of Clinical Neurosciences, University of Oxford, Level 6, West Wing John Radcliffe Hospital, OX3 9DU, Oxford, UK.
Ruxandra DafincaNuffield Department of Clinical Neurosciences, University of Oxford, Level 6, West Wing John Radcliffe Hospital, OX3 9DU, Oxford, UK.
Emily FenebergDepartment of Neurology, Technical University of Munich School of Medicine and Health, Munich, Germany.
Kevin TalbotNuffield Department of Clinical Neurosciences, University of Oxford, Level 6, West Wing John Radcliffe Hospital, OX3 9DU, Oxford, UK.
Martin R TurnerNuffield Department of Clinical Neurosciences, University of Oxford, Level 6, West Wing John Radcliffe Hospital, OX3 9DU, Oxford, UK.
Alexander G ThompsonNuffield Department of Clinical Neurosciences, University of Oxford, Level 6, West Wing John Radcliffe Hospital, OX3 9DU, Oxford, UK. alexander.thompson@ndcn.ox.ac.uk.

Funding

Medical Research Council MR/T006927/1Motor Neurone Disease Association Thompson/Jan20/952-795
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40495245
PMCPMC12153176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.